Active substanceVinorelbineVinorelbine
Similar drugsTo uncover
  • Velbin
    concentrate d / infusion 
    AKTAVIS GROUP, AO     Iceland
  • Vinelbin
    concentrate d / infusion 
  • Winkater
    concentrate d / infusion 
  • Vinorelbine
    concentrate d / infusion 
    FARM STANDART, OJSC     Russia
  • Vinorelbine
    concentrate d / infusion 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Vinorelbine medak
    concentrate d / infusion 
    medac GmbH     Germany
  • Vinorelbine-Teva
    concentrate d / infusion 
  • Marex
    concentrate d / infusion 
    LENS-PHARM, LLC     Russia
  • Navelbin
    capsules inwards 
  • Navelbin
    concentrate d / infusion 
  • Cituvin®
    concentrate d / infusion 
    BIOCAD, CJSC     Russia
  • Dosage form: & nbspcapsules
    Composition:

    Dosage

    20 mg

    30 mg

    Active substance:

    vinorelbine tartrate in terms of vinorelbine base

    27.70 mg

    41.55 mg

    20.00 mg

    30.00 mg

    Excipients:

    ethanol anhydrous

    5.00 mg

    7.50 mg

    purified water

    12.50 mg

    18.75 mg

    glycerol

    2.00 mg

    3.00 mg

    macrogol 400

    sk. demand, up to 175.00 mg

    sk. demand, up to 262.50 mg

    Capsule shell:

    gelatin

    67.31 mg

    101.89 mg

    glycerol 85%

    37.98 mg

    55.63 mg

    Anidrizor 85/70 (Dsorbitol, 1,4-sorbitan, mannitol, higher polyols)

    10.54 mg

    15.96 mg

    medium chain triglycerides

    sk. demand.

    sk. demand.

    PHOSAL 53 MST

    (phosphatidylcholine, glycerides, ethanol)

    sk. demand.

    sk. demand.

    iron oxide red E172

    -

    0.050 mg

    iron oxide yellow E172

    0.55 mg

    -

    titanium dioxide E171

    1.16 mg

    1.50 mg

    Composition of ink for printing on food products: E120, hypromellose, propylene glycol


    Description:

    Capsules 20 mg

    Soft gelatin capsules (oval, size 3), light brown, with the inscription "N20" in red.

    Capsules 30 mg

    Soft gelatin capsules (oblong, size 4), pink, with the inscription "N30" in red.

    The contents of the capsules are a viscous solution from light yellow to orange-yellow.

    Pharmacotherapeutic group:antitumor agent, alkaloid.
    ATX: & nbsp

    L.01.C.A.04   Vinorelbine

    Pharmacodynamics:

    Vinorelbine is an antitumor agent of plant origin from the group of semisynthetic vinca alkaloids isolated from a plant of the genus Vinca Periwinkle. Violates the polymerization of tubulin in the process of cellular mitosis. It blocks mitosis of cells in the metaphase G2-M stage, causing cell death during interphase or subsequent mitosis. Acts mainly on mitotic microtubules; when high doses are applied, it also affects axonal microtubules. The effect of spiral tubulin, caused by vinorelbine, is less pronounced than that of vincristine.

    Pharmacokinetics:
    Absorption
    After oral administration vinorelbine rapidly absorbed from the gastrointestinal tract
    tract. The maximum absorption time Tmax is in the range of 1.5 to 3 hours with a peak concentration in the blood (Cmax) of about 130 ng / ml after taking the drug at a dose of 80 mg / m2. Absolute bioavailability averages 40%, simultaneous intake of food does not affect the degree of absorption of vinorelbine.
    Distribution
    The volume of vinorelbine distribution is high, averaging 21.2 l / kg (range 7.5-39.7 l / kg), which indicates an extensive distribution of vinorelbine in tissues.
    Binding to plasma proteins is insignificant - 13.5%, vinorelbine in large quantities binds to blood cells, especially with platelets (about 78%). There is a significant seizure of vinorelbine with a pulmonary tissue, where a concentration of 300 times higher than in the blood plasma is achieved. Vinorelbine is not found in the brain tissues.
    Metabolism
    Vinorelbine is biotransformed in the liver under the action of the cytochrome P450 isoenzyme CYP3A4. All metabolites are identified and inactive, with the exception of 4-O-deacetyl-vinorelbine, which is the main active metabolite in the blood plasma. Sulfo- and glucuronic conjugates were not detected.
    Excretion
    The average half-life of vinorelbine in the final phase of elimination is about 40 (27.7-43.6) hours. Systemic clearance of vinorelbine is high and approaches the rate of blood flow in the liver, is on average
    0.72 l / h / kg (0.32-1.26 l / h / kg). Vinorelbine mainly excreted in the bile in unchanged form and in the form of metabolites. The kidneys produce less than 20% of the intravenously administered dose, mainly as a starting material. Pharmacokinetics in specific patient groups
    Patients with impaired hepatic function
    The pharmacokinetics of vinorelbine does not change in patients with hepatic insufficiency. Nevertheless, as a precautionary measure, it is recommended to reduce the dose to 20 mg / m2 of the body surface and carefully monitor hematological parameters in patients with moderate or severe hepatic impairment.
    Patients with impaired renal function
    The effect of renal dysfunction on the pharmacokinetic properties of vinorelbine has not been investigated. However, due to the low level of renal elimination, a decrease in vinorelbine dose in the case of decreased renal function is not indicated.
    Elderly patients
    The pharmacokinetics of vinorelbin in elderly patients (≥ 70 years) does not change. However, since elderly patients may be weakened, precautions should be taken when increasing the dose of vinorelbine.
    Indications:

    - non-small cell lung cancer;

    - Common breast cancer.

    Contraindications:
    • hypersensitivity to vinca alkaloids or other components of the drug;
    • initial absolute number of neutrophils <1,500 cells / μl of blood;
    • the initial number of platelets <100 000 cells / μl of blood;
    • diseases and conditions leading to a decrease in absorption in the gastrointestinal tract;
    • significant resection of the stomach or duodenum in the anamnesis;
    • Infectious diseases on the day of initiation of therapy or transferred during the last 2 weeks;
    • severe liver function failure, not associated with the tumor process;
    • the need for continuous oxygen therapy - in patients with a lung tumor;
    • pregnancy and the period of breastfeeding;
    • Children under 18 years of age (safety and efficacy of vinorelbin in children have not been studied);
    • simultaneous application with the vaccine against yellow fever.
    Carefully:
    Caution should be used drug Navelbin in patients with
    ischemic heart disease in anamnesis, in patients with severe general condition, with hepatic insufficiency of the average severity, with simultaneous application with strong inhibitors or inducers of isoenzyme CYP3A4.
    Pregnancy and lactation:Drug Navelbin is contraindicated during pregnancy due to embryotoxic effects. Drug Navelbin is contraindicated in the period of breastfeeding. Breastfeeding should be discontinued before taking the drug.
    Dosing and Administration:
    For oral administration.
    Capsules should be taken with meals. Capsules should be swallowed whole, squeezed with water, without chewing and not rassasyvaya in the mouth.
    Frequency of drug administration and duration of treatment are determined by the attending physician.
    Recommended doses of the drug Navelbin (capsules) depending on the patient's body surface area (BSA)

    BSA (m2)

    The recommended dose is 60 mg / m2

    The recommended dose is 80 mg / m2

    total single dose (mg)

    total single dose (mg)

    0.95 to 1.0

    60

    80

    1.05 to 1.14

    70

    90

    1.15 to 1.24

    70

    100

    1.25 to 1.34

    80

    100

    1.35 to 1.44

    80

    110

    From 1.45 to 1.54

    90

    120

    1.55 to 1.64

    100

    130

    1.65 to 1.74

    100

    140

    1.75 to 1.84

    110

    140

    1.85 to 1.94

    110

    150

    > 1,95

    120

    160


    For patients with body surface area 2m2, the total single dose should not exceed 120 mg per week with the administration of the drug at a dose of 60 mg / m2 and 160 mg per week at a dose of 80 mg / m2.
    Dosage should be determined on the basis of hematological parameters.
    When the absolute number of neutrophils is reduced to less than 1500 cells / μl of blood and / or thrombocytopenia <100,000 cells / μl of blood, the drug administration is postponed until their number is restored.
    Mode of monotherapy
    - The first three steps
    The recommended dose is 60 mg / m2 once a week.
    - Follow-up techniques
    After the third dose, it is recommended to increase the dose to 80 mg / m2 once a week.
    An increase in the dose is possible if, within three weeks of taking the drug at a dose of 60 mg / m2 per week, the absolute number of neutrophils (ACH) has never decreased below 500 cells / μl, or decreased to a level of 500-1000 cells / μl, not more than once.

    AFN during the first 3 cycles of taking the drug at a dose of 60 mg / m2 in Week

    The recommended dose for beginning of the next dose (mg / m2)

    >1 000

    80

    ≥500 and <1,000 (1 episode)

    80

    ≥500 and <1,000 (2 episodes)

    60

    <500

    60

    If during the period of application of the drug in a dose of 80 mg / m2 AFN becomes less than 500 cells / μl or more than one time decreases to a level of 500-1000 cells / μl, the next administration of the drug should be postponed until the ACN is restored and take the drug at a dose of 60 mg / m2 a week for the next three weeks.

    To determine whether it is possible to increase the dose again from 60 mg / m2 up to 80 mg / m2 hematological parameters should be assessed.

    AFC after taking

    The recommended dose for

    preparation

    the beginning of the next appointment

    in a dose of 80 mg / m2 in Week

    (mg / m2)

    >1 000

    80

    > 500 and <1,000 (1 episode)

    80

    > 500 and <1,000 (2 episodes)

    60

    <500

    60

    Combined therapy regimen

    Doses and regimens should be adapted for the treatment protocol.

    For combined regimes in which the oral administration of the drug Navelbin capsules alternates with the intravenous administration of the drug Navelbin concentrate for the preparation of a solution for infusion, it should be taken into account that the oral administration at doses of 60 mg / m2 and 80 mg / m2 leads to a concentration of vinorelbine in the blood, comparable to the concentration achieved by intravenous administration of the drug in doses of 25 mg / m2 and 30 mg / m2 respectively.

    Side effects:

    Adverse reactions are systematized according to the system-organ classes and are listed according to the following gradation: very frequent - 1/10 appointments (≥ 10%); frequent - 1/100 appointments (≥1% but <10%); infrequent - 1/1000 appointments (≥0.1% but < 1%); rare - 1/10000 appointments (≥0.01% but <0,1%); very rare - less than 1/10000 appointments (<0.01%); post-marketing messages, the frequency can not be estimated from the available data.

    Infectious and parasitic diseases

    Often: bacterial, viral and fungal infections without neutropenia, various localizations.

    Often: bacterial, viral or fungal infections resulting from myelosuppression and / or immunosuppression (neutropenic infection) are usually reversible with appropriate treatment.

    Frequency unknown: neutropenic sepsis.

    Violations of the blood and lymphatic system

    Often: myelosuppression, leading to neutropenia (the smallest number of neutrophils is observed on the 7-10th day from the start of therapy, recovery occurs in the next 5-7 days, cumulation of hematotoxicity is not observed), anemia, leukopenia, thrombocytopenia.

    Often: grade 4 neutropenia, associate from increase body temperature above 38 ° C, febrile neutropenia.

    Infrequently: sepsis, septicemia.

    Disorders from the metabolism and nutrition

    Frequency unknown: Heavy hyponatremia.

    Disorders of the psyche

    Often: insomnia.

    Disturbances from the nervous system

    Often: neurological disorders, including reduction or loss

    tendon reflexes.

    Often: neuromotor disorders, headache, dizziness, a disorder of taste perception.

    Infrequently: ataxia.

    Disturbances on the part of the organ of sight

    Often: impaired visual perception.

    Heart Disease

    Infrequently: heart failure,disturbance of the heart rhythm.

    Frequency unknown: myocardial infarction patients with heart disease in

    history or risk factors of cardiovascular disease,cardiovascular diseases.

    Vascular disorders

    Often: arterial hypertension,arterial hypotension.

    Disturbances from respiratory system, chest organs and

    the mediastinum

    Often: shortness of breath, cough.

    Disorders from the gastro-intestinal tract

    Often: nausea, vomiting, diarrhea,anorexia, stomatitis, abdominal pain, constipation,

    gastric disorders.

    Often: esophagitis, dysphagia.

    Infrequently: paralytic intestinal obstruction.

    Frequency unknown: gastrointestinal bleeding.

    Disorders from the liver and bile ducts

    Often: abnormal liver function.

    Disturbances from the skin and subcutaneous fabrics

    Often: alopecia (usually mild degree).

    Often: skin reactions.

    Musculoskeletal disorders system and connective tissue

    Often: arthralgia, pain in the temporal-mandibular joint, myalgia.

    Infringements from kidneys and urinary tract

    Often: dysuria, other genitourinary violations.

    General disorders and disorders in place introduction of

    Often: weakness, bad state of health, fever.

    Often: Pain, including pain in the area a tumor, a chill.

    Laboratory and instrumental data

    Often: decrease in body weight.

    Often: increase in body weight.

    Overdose:
    The main toxic effect due to an overdose is
    suppression of bone marrow function, sometimes in combination with infection, fever, paralytic intestinal obstruction and impaired liver function.
    The specific antidote is unknown.
    In case of an overdose, it is necessary to hospitalize the patient and carefully monitor the functions of vital organs.Appropriate measures should be taken, such as blood transfusion, administration of antibiotics, growth factors. Monitoring of liver function is recommended.
    Interaction:
    Vaccines: in connection with the immunosuppressive effect of the drug and the possibility of developing severe infections, it is not recommended during the period of chemotherapy to carry out vaccination with live (weakened) vaccines.
    Itraconazole: an increase in the neurotoxicity of vinorelbine due to
    increase in vinorelbine concentration in plasma as a result of its decrease
    metabolism in the liver.
    Phenytoin: possibly reducing the anticonvulsant effect of phenytoin,
    decreased efficacy and increased toxicity of vinorelbine.
    Cystatin: There is no mutual influence in the combined use of vinorelbine and cisplatin. However, the incidence of granulocytopenia when using a combination of vinorelbine with cisplatin is higher than in the case of
    monotherapy with vinorelbine.
    Cytotoxic: possible mutual aggravation of side effects, in the first place
    turn - myelosuppression.
    Oral anticoagulants: possible mutual aggravation of side effects,should be systematically monitored by INR (the international normalized relationship), as well as careful monitoring of the general condition of the patient.
    Cyclosporin, tacrolimus: severe immunosuppression with risk
    lymphoproliferation.
    Inhibitors of the CYP isoenzyme ZA4 (for example, ketoconazole): an increase in the neurotoxicity of vinorelbine due to an increase in vinorelbine concentration in the blood plasma as a result of a decrease in its metabolism in the liver.
    Inductors of the CYP isoenzyme ZA4 (for example, rifampicin): decline
    efficacy and increased toxicity of vinorelbine due to increased metabolism in the liver.
    Inductors and inhibitors of cytochrome P450: a change in the pharmacokinetics of vinorelbine is possible.
    Mitomycin C: increased pulmonological toxicity of mitomycin (risk of bronchospasm, acute respiratory failure, rare cases of interstitial pneumonia).
    Inductors and inhibitors of P-glycoprotein: since it is known that vinca alkaloids are a substrate for P-glycoprotein, caution should be exercised when using the drug Navelbin together with preparations that modify the function of this transport protein.
    Antiemetic drugs, such as 5HTZ antagonists (eg, ondansetron, granisetron) Do not affect the pharmacokinetics of the drug Navelbin.
    Special instructions:
    - Treatment with the drug Navelbin capsules should be carried out under the supervision of a doctor who has experience with antitumor drugs.
    - Therapy is carried out under strict hematological control, determining the number of leukocytes, neutrophils, platelets, as well as the concentration of hemoglobin before each next dose of the drug.
    - In case of suspected co-infection on the day of initiation of therapy, the patient should be examined and the benefit-risk ratio should be evaluated when deciding whether to administer the drug.
    - If dyspnea, cough, or hypoxia of unexplained etiology appears, the patient should be examined to exclude pulmonary toxicity.
    - Taking Navelbin Capsules is associated with a risk of developing nausea / vomiting. Primary prophylaxis with the use of antiemetics is recommended. In the case of vomiting within the first few hours after taking the drug, do not take a second dose of the drug.
    - The contents of the capsule are irritating.If the patient mistakenly chewed or squeezed the capsule, immediately rinse the oral cavity with 0.9% sodium chloride solution or water.
    - In case of mechanical damage to the capsule, contact with liquid contents can lead to burns of the skin, mucous membranes or eyes. If this
    the affected areas should be washed immediately and thoroughly with 0.9% sodium chloride solution or water. Damaged capsules must be transferred to a medical institution for the purpose of destroying properly.
    - Nabelbin capsule preparation should not be used concomitantly with the administration of X-ray therapy, especially exciting the liver area.
    - The drug Navelbin should be used with caution with strong inhibitors or inducers of the isoenzyme CYP3A4; simultaneous use of the drug with phenytoin, itraconazole, live attenuated vaccines is not recommended.
    - The composition of the capsule shell is sorbitol. The drug should not be taken to patients suffering from intolerance to fructose.
    Effect on the ability to drive transp. cf. and fur:Special studies on the effect of the drug on the ability to drive vehicles and control mechanisms have not been conducted.However, patients are not advised to drive vehicles and engage in other potentially hazardous activities requiring increased concentration and speed of psychomotor reactions if they experience adverse reactions that may affect the performance of this activity (eg, dizziness, visual impairment).
    Form release / dosage:Capsules 20 mg, 30 mg.
    Packaging:

    One capsule in a blister of PVC / PVDC and aluminum foil.

    One blister with instructions for use in a pack of cardboard.

    Storage conditions:
    At a temperature of 2 ° C to 8 ° C.
    Keep out of the reach of children.

    Shelf life:

    3 of the year. Do not use after the expiration date stated on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LS-000704
    Date of registration:07.02.2011
    The owner of the registration certificate:Pierre Fabre Medication ProductionPierre Fabre Medication Production France
    Manufacturer: & nbsp
    Representation: & nbspPIER FABR PIER FABR France
    Information update date: & nbsp23.10.15
    Illustrated instructions
      Instructions
      Up